Crossmark

Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy

Crossref DOI link: https://doi.org/10.1136/bmjresp-2018-000277

Published Online: 2018-04-21

Published Print: 2018-04

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Franzen, Daniel

Haile, Sarah R

Kasper, David C

Mechtler, Thomas P

Flammer, Andreas J

Krayenbühl, Pierre A

Nowak, Albina https://orcid.org/0000-0002-4119-5516
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01632111 at ClinicalTrials.gov

Documents that mention this clinical trial

Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy
https://doi.org/10.1136/bmjresp-2018-000277
Funding

Funding for this research was provided by:

Sanofi Genzyme

Shire